The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the ...

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...

The agency approved the drug based on data from the DESTINY-Breast06 trial, which included patients who had tumors with very low HER2 expression.

Patients on the firm's SSTR-targeted radiopharmaceutical had improved progression-free survival compared to patients on an mTor inhibitor in a Phase III trial.

The trial will include patients with non-small cell lung, breast, ovarian, gastric, esophageal, and colorectal cancers.

With this approval, patients who receive the anti-amyloid drug biweekly for 18 months can then consider switching to a monthly dosing regimen.

In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...

HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...

Despite Leqembi's initial slow sales, the firm's CEO cited areas for the drug's growth and ambitions for an antisense ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and transthyretin amyloidosis.

The change in policy at the health system follows the death of a DPD deficient patient and comes during a period of intense ...

Doctors and patient advocates supporting pretreatment testing at times challenged FDA and other experts who aren't swayed by available evidence.